Investigational drug · Phase 2
IMM01-STEM
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Muscle Performance, Sarcopenic Obesity, Muscle Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "IMM01-STEM"
First trial start
2022
Sep 13, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMM01-STEM", any sponsor or status.
Conditions studied
As listed on its trial records.
- Muscle Performance
- Sarcopenic Obesity
- Muscle Atrophy
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "IMM01-STEM" as an intervention, largest first.
- Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle WeaknessActive, not recruiting
Immunis, Inc.Industry
NCT06600581 · 55 participants (planned) · Start Dec 19, 2024 · Primary completion Jul 15, 2026
Drug: IMM01-STEM; IMM01-STEM alternating with placebo (saline) · For: Muscle Performance; Sarcopenic Obesity
Sites: Garden Grove, California; Pomona, California; Lenexa, Kansas · 4 sites in all
Immunis, Inc.Industry
NCT05211986 · 13 participants · Start Sep 13, 2022 · Primary completion Jul 27, 2026
Drug: IMM01-STEM · For: Muscle Atrophy
Sites: Irvine, California; Orange, California
- INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITYTemporarily not available
Immunis, Inc.Industry
NCT06784297
Drug: IMM01-STEM · For: Sarcopenia; Obesity and Obesity-related Medical Conditions
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.